Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological Activation of Hypoglossal Motor Nucleus for OSA Aim 2
NCT03858751Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Mar 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine, oxybutynin in obstructive sleep apnea (OSA), sponsored by Brigham and Women's Hospital. Started Mar 2019; status: recruiting.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03858751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858751.